@article{oai:repo.qst.go.jp:00049324,
 author = {Hayashi, Kazuhiko and Koto, Masashi and Demizu, Yusuke and Jun-ichi, Saitoh and Suefuji, Hiroaki and Okimoto, Tomoaki and Ohno, Tatsuya and Shioyama, Yoshiyuki and Takagi, Ryo and Ikawa, Hiroaki and Nemoto, Kenji and Nakano, Takashi and Kamada, Tadashi and the, Japan Carbon‐Ion Radiation Oncology Study Group and Hayashi, Kazuhiko and Koto, Masashi and Takagi, Ryo and Ikawa, Hiroaki and Kamada, Tadashi},
 issue = {5},
 journal = {Cancer Science},
 month = {Apr},
 note = {A retrospective multicenter study was conducted to assess the clinical outcomes of carbon-ion radiotherapy for head and neck malignancies (Japan Carbon-Ion Radiation Oncology Study Group [J-CROS] study: 1402 HN). We evaluated the safety and efficacy of carbon-ion radiotherapy in patients with major salivary gland carcinoma. Sixty-nine patients treated with carbon-ion radiotherapy at 4 Japanese institutions were analyzed. Thirty-three patients (48%) had adenoid cystic carcinomas, 10 (14%) had mucoepidermoid carcinomas, and 26 (38%) had other disease types. Three patients (4%) had T1 disease, 8 (12%) had T2, 25 (36%) had T3, and 33 (48%) had T4. The median radiation dose was 64 Gy (relative biological effectiveness) in 16 fractions. The median gross tumor volume was 27 mL. The median follow-up period was 32.7 months. The 3-year local control rate and overall survival rate were 81% and 94%, respectively. Regarding acute toxicities, 7 patients had grade 3 mucositis and 7 had grade 3 dermatitis. Regarding late toxicities, 1 patient had grade 3 dysphagia and 1 had a grade 3 brain abscess. No grade 4 or worse late reactions were observed. In conclusion, definitive carbon-ion radiotherapy was effective with acceptable toxicity for major salivary gland carcinomas.},
 pages = {1576--1582},
 title = {A retrospective multicenter study of carbon-ion radiotherapy for major salivary gland carcinomas: subanalysis of J-CROS 1402 HN},
 volume = {109},
 year = {2018}
}